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ÖZET
Tiroid hormon direnci sendromu (RTH) genellikle otozo-
mal dominant kalitim gösteren nadir bir hastalıktır. Tiro-
id hormon direnci olan hastalar genellikle ötiroid olurlar 
fakat nadir de olsa tirotoksikoz veya hipotiroidizm belirti 
ve bulguları ile seyredilebilir. Biz bu yazıda ilginç bir send-
rom olarak tiroid hormon direnci olan fakat aile öyküsü 
olmayan bir olgu sunulmaktadır. Olgumuzda yüksek se-
rum tiroid hormon düzeyleri ve normal TSH düzeylerine 
rağmen guatr, kilo alımında artış ve normal zeka durumu 
gözlendi.
Anahtar kelimeler: Tiroid hormon direnci, obezite, guatr
ABSTRACT
Resistance to thyroid hormone syndrome (RTH) is a rare 
disorder, usually inherited as an autosomal dominant trait. 
Patients with RTH are usually euthyroid but can occasion-
ally present with signs and symptoms of thyrotoxicosis or 
rarely with hypothyroidism. We present a patient with in-
teresting syndrome as RTH but no family history. Goiter, 
increased weight gain and normal mental status were ob-
served despite high serum thyroid hormones and normal 
TSH levels.
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INTODUCTION
Thyroid hormone resistance (RTH) describes as the 
thyroid hormone levels are elevated with variable 
refractoriness to hormone action in target tissues but 
the thyroid stimulating hormone (TSH) level is not 
suppressed, or not completely suppressed as would 
be expected.1 RTH is a rare syndrome, and inci-
dence is variously as 1 in 50,000 or 1 in 40,000 live 
births.2 Since the first description of RTH in 19673, 
more than 700 individual with RTH belonging to 
about 250 unrelated families have been identified 
up to day.4-5 The majority of RTH cases that have 
been described are dominantly inherited with highly 
variable clinical features.6
The genetic studies have shown that most mu-
tations are found in three exons in the thyroid hor-
mone receptor-beta (THRβ) gene on chromosome 
3 at”hot spot” regions. Most of the disease-causing 
mutations are clustered in the ligand-binding do-
main of THRβ, residues 310-353 (cluster 1), 429-
461 (cluster 2), and 234-282 (cluster 3)7-8 Clinical 
manifestations are extremely variable, the majority 
of patients being euthyroid according with a gen-
eralized  form  of  RTH  while  a  minority  of  them 
presents with thyrotoxic features standing for a less 
pronounced resistance at the peripheral tissue level. 
Moreover, there is only one case reported in the 
literature of isolated resistance to peripheral tissue 
level, presenting with a severe hypothyroid state.9
We herein reported a rare and interesting syn-
drome in a case with RTH but no family history.
CASE
A man with 44 year-old was admitted to endocrinol-
ogy department due to fatigue, weakness, constipa-
tion, and increased need for sleep. These complaints 
were continued for one year. He had initially given 
for  two  months  propylthiouracil  because  of  high Y. İ. Kibar ve ark. A rare syndrome 346
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free T3 (fT3) and free T4 (fT4) levels in other clinic, 
but these complaints were increased. When he came 
to our polyclinics, he had stopped propylthiouracil 
treatment with his own decision since 6 months ago. 
He has no prior history of hypothyroidism. There 
were no chronic illnesses or previous thyroidal op-
eration. In his family history, his father, mother, sis-
ters and brothers do not have any thyroid disease.
Physical examination
The  vital  signs  were  blood  pressure  120/70  mm 
Hg,  pulse  82/minute,  respiratory  rate  14/minute, 
temperature 36.0° Celsius. His height was 165 cm 
and  his  weight  was  106  kg.  He  suffered  obesity 
and his body mass index was 39 kg/m2. He had a 
nodular goiter (grade II). There was no neck tender-
ness. Hand fine tremor was not appreciated. Normal 
deep tendon reflexes were observed. But, there were 
markedly abdominal obesity and 2 cm hepatomeg-
aly. Bowel sound was hypoactive. Other systemic 
examinations were normal.
Laboratory values
Free T3 (fT3) and free T4 (fT4) levels were high, 
but TSH level was not suppressed and, it was in-
appropriately normal level. Free T3 was found 7.5 
pg/mL (normal range 1.8-4.2). Free T4 was found 
3.27 ng/mL (normal range 0.8-1.9). TSH was found 
3.19 mIU/mL (normal range 0.4-4.0). In spite of 
the markedly elevated free T4 and free T3, the pa-
tient was clinically hypothyroid. TPO antibody was 
<10.0 IU/mL ( normal range 0-35), thyroglobulin 
was 11.16 ng/mL (normal range 1.15-35.0), anti-
thyroglobulin was 20>IU/mL (normal range 0-40). 
At thyroid ultrasound, his gland was viewed as a 
heterogeneous and nodular pattern (5x5.5 mm in 
right lobe, 6.6x9 mm in left lobe, respectively). In 
the thyroid scintigraphy, the expected level of in-
volvement and activity in both lobes were homo-
geneous. The anterior pituitary hormones as FSH, 
LH, prolactin, growth hormone and fasting morn-
ing cortisol levels were normal range. In addition, 
serum ferritin, total testosterone, free testosterone, 
dehydroepiandrosterone sulfate, sex hormone bind-
ing  globulin,  and  angiotensin-converting  enzyme 
levels were normal. Alpha subunit of TSH level was 
0.30 IU/L in normal limit (normal range 0 to 0.80). 
No  pituitary  TSH  secreting  adenoma  (TSHoma) 
was  determined  in  pituitary  MR  by  radiologists. 
As a result, we considered thyroid hormone resis-
tance and we performed TRH stimulation test. After 
intravenous TRH injection bolus (400 ug), serum 
TSH concentration increased from 1,40 U/mL to a 
peak of 17,6 U/mL at 30 min (Table 1). In evalua-
tion of echocardiography, presystolic ejection time 
was observed as 52 msec below the normal range 
(Figure 1). In this state, Refetoff syndrome (thyroid 
hormone resistance) was considered and, levothy-
roxine 50 microgram per day was started. Later, his 
complaints were reduced in the controls.
Figure 1. Presistolic ejection time in the patientY. İ. Kibar ve ark. A rare syndrome 347
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Table 1. Summary of pattern associated with elevated 
TSH during TRH test
Time (min) TSH (mIU/mL) f T 3( pg/mL) f T4( ng/dL)
0 1.40 6.32 2.87
30 17.6 5.90 2.80
60 10.6 5.80 2.92
120 6.05 7.76 2.88
DISCUSSION
Thyroid hormone resistance is a rare disorder and 
usually  dominantly  inherited  manner  with  highly 
variable  clinical  features.  Characteristically,  thy-
roid function tests are elevated free T4 and free T3 
concentrations with inappropriately non-suppressed 
TSH. The clinical expression of this syndrome is 
heterogeneous. Exacerbate goiter is the most com-
mon clinical finding but the classic features include 
cognitive ability, attention-deficit hyperactivity dis-
order, poor school performance, delays in growth 
and  development,  hypercholesterolemia,  signs  of 
hypothyroidism  as  deaf  mutism,  nystagmus,  epi-
physeal  dysplasia,  and  delayed  bone  age  and/or 
tachycardia  are  usually  diagnosed  in  childhood. 
Our patient presented with markedly elevated thy-
roid  hormone  and  normal TSH  levels  whereas  a 
mild RTH phenotype. In our case, diagnosis of RTH 
has remained up to adulthood due to no significantly 
clinical findings. His clinically features such as goi-
ter, increased weight gain and normal mental status 
were observed. It is important that many patients 
with  RTH  are  either  asymptomatic  or  have  non-
specific symptoms like our patient. The genetic het-
erogeneity in patients with RTH is the most likely 
explanation for variable clinical findings.
Typically most or all tissues are resistant to thy-
roid hormone, so despite raised measures of serum 
thyroid hormone the individual may appear euthy-
roid. Moreover, the severity of hormonal resistance 
varies among different tissues in an affected indi-
vidual, and also varies among different subjects car-
rying the same gene mutation. The reasons for this 
variability are poorly understood. According to our 
findings, the only index case presented with elevat-
ed TSH and no symptoms of hypothyroidism, but 
other his family members were asymptomatic and 
phenotypes were normal. In physical examination, 
goiter was the most significantly clinical abnormal-
ity in our patient. This finding pointed out that high 
serum TSH levels with increased biological activity 
might be responsible for the goiter and maintenance 
of high thyroid hormone levels in RTH. He has nor-
mal thyroid hormone levels and normal TSH while 
taking 100 mg L-T4 per day.
Sinus tachycardia is very common in patients 
with  RTH,  some  studies  reporting  frequency  as 
high as 80%12 One previously study13 showed mild 
tachycardia in RTH patients with an average rest-
ing heart rate of 83 beats/min (range 57-107). The 
liver and pituitary express predominantly TRβ1 and 
TRβ2 respectively, whereas myocardium expresses 
TRα1. Therefore mutations in the TRβ gene in RTH 
are associated with pituitary and liver resistance, as 
exemplified by normal serum sex-hormone-binding 
globulin  and  non-suppressed  TSH  levels  seen  in 
patients, while the tachycardia seen in many RTH 
cases may represent retention of cardiac sensitivity 
to elevated thyroid hormones acting via a normal 
TRα.15 Interestingly, although positive correlations 
between free T3 and heart rate have been shown in 
RTH, heart rate was clearly normal range in spite 
of high free T3 levels in our index case. Moreover, 
normal presystolic ejection time was demonstrated 
during echocardiographic evaluation. According to 
our finding, cardiac affects of RTH were negligible 
in our case.
Neurophysiological abnormalities such as at-
tention deficit hyperactivity disorder in childhood or 
language development problems manifested by poor 
reading skills, dyslexia and problems with articu-
lation have been documented in a large number of 
patients with RTH.4,10,11 But, these neurophysiologi-
cal symptoms were not determined in our patient; 
his only symptom of RTH was obesity. Obesity was 
much more pronounce than cases of heterozygous 
RTH. Moreover, his obesity has worsened due to ces-
sation of LT4 drug treatment over a 6-month period. 
His weight was increase approximately 12 kg in 6 
months. Mitchell CS et al.14 recently demonstrated 
that energy intake in RTH subjects was increased by 
40%, with marked hyperphagia particularly evident 
in children. Basal mitochondrial substrate oxidation 
is increased and energy production in the form of 
ATP synthesis is decreased in the muscle of RTH 
patients and that resting oxidative phosphorylation 
is uncoupled in this disorder.14Y. İ. Kibar ve ark. A rare syndrome 348
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At  least  three  different  molecular  alterations 
may cause reduced sensitivity to thyroid hormones: 
(a) mutations in the gene encoding TRβ isoform 
causing RTH, (b) mutations of the specific TH trans-
porter, monocarboxylate transporter 8 (MCT8), and 
(c) mutations in selenocysteine insertion sequence 
binding protein 2 (SECISBP2) which reduces the 
synthesis of selenoproteins, including the TH deio-
dinases.16 Kale BK et al.17 previously demonstrated 
that a Turkish family with RTH whose proband a 
19-year-old  male,  presented  with  diffuse  goiter, 
nervousness,  and  palpitation.  Gene  sequencing 
revealed a mutation in one allele of the TRβ gene 
in the proband, his two brothers, and father. It in-
volved the substitution of the normal cytosine 1642 
with a thymidine, resulting in the replacement of 
the normal proline 453 with a serine (P453S) in the 
T3-binding domain of the TRβ. Unfortunately, we 
could not evaluate to genetic mutations in this fam-
ily because of technical failure.
In conclusion, routine investigation by sensi-
tive TSH may provide to detect a greater number 
of patients in outpatient’s clinics. It is important to 
remember that the patients with RTH may display 
only minimal elevation of serum TSH despite high 
thyroid hormones levels.
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